Aminopterin
54-62-6Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1TVZGACDUOSZQKY-LBPRGKRZSA-NAminopterin can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts.
3.0X103 mg/L
Soluble in aqueous sodium hydroxide solutions
In water, 3.0X103 mg/L at 25 °C /Estimated/
Clusters of yellow needles. Used as a rodenticide, medicine and rodenticide. Not registered as a rodenticide in the U.S. (EPA, 1998)
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H300 (100%): Fatal if swallowed [Danger Acute toxicity, oral]
P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 44 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard Traits - Developmental Toxicity; Reproductive Toxicity
L-Glutamic acid, N-4-(2,4-diamino-6-pteridinyl)methylaminobenzoyl-: Does not have an individual approval but may be used under an appropriate group standard
The New Jersey Worker and Community Right to Know Act requires public and private employers to provide information about hazardous substances at their workplaces. (N.J.S.A. 34:5A-1 et. seq.)
A folate antagonist; When used as a medication during pregnancy, increases the risk of abortions and malformations; Bone marrow toxicity: hypoplasia of all elements including leukopenia and thrombocytopenia; [HSDB] Increases risk of malformations if taken during pregnancy; [REPROTOX] May cause irritation; Targets the blood; [MSDSonline]
Aminopterin is an amino derivative of folic acid which binds competitively to the dihydrofolate reductase enzyme to block tetrahydrofolate synthesis. Tetrahydrofolate is essential in the production of purines and pyrimadines, thus it's deficiency results in a reduction of DNA, RNA and protein synthesis.
Antagonizes the utilization of folic acid by the body, an antimetabolite.
Aminopterin /was a/ commonly used drug that inhibited digestive-absorptive mechanisms /by/ inhibiting folate transport and cell proliferation. /From table/
Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033)
Used as a rodenticide and medicine; [Hawley] Formerly used in the treatment of childhood leukemia; [HSDB]
Farming (Pesticides) [Category: Industry]
Is a folic acid antagonist
Rodenticide
MEDICATION
Aminopterin Syndrome Sine Aminopterin (ASSA, OMIM 600325) is an embryopathy caused by maternal treatment with the olic acid antagonist aminopterin has been recognized since 1952 when aminopterin was used as an abortifacient. Aminopterin is an antimetabolite drug used in treatment of cancer and autoimmune diseases.
Prepared from 2,4,5,6-tetraminopyrimidine sulfate, 2,3-dibromopropionaldehyde and p-aminobenzoylglutamic acid: Seegar et al, J Am Chem Soc 69, 2567 (1947); from 6-bromomethyl)-2,4-diaminopteridine hydrogen bromide: Piper, Montgomery, J Heterocycl Chem 11, 279 (1974).
54-62-6DTXSID3022588CHEMBL376180CHEBI:22526Orange-yellow solid; [HSDB]
化学的特性Aminopterin is a white to yellow powder; commonly used as the dihydrate which forms clustersof yellow needles
Releases of CERCLA hazardous substances are subject to the release reporting requirement of CERCLA section 103, codified at 40 CFR part 302, in addition to the requirements of 40 CFR part 355. Aminopterin is an extremely hazardous substance (EHS) subject to reporting requirements when stored in amounts in excess of its threshold planning quantity (TPQ) of 500 or 10,000 lbs. Extremely hazardous substances that are solids are subject to either of two threshold planning quantities ... The lower quantity applies only if the solid exists in powdered form and has a particle size less than 100 microns; or is handled in solution or in molten form; or meets the criteria for a National Fire Protection Association (NFPA) rating of 2, 3 or 4 for reactivity. If the solid does not meet any of these criteria, it is subject to the upper ... threshold planning quantity ... .
Acute Tox. 1 (100%)
Teratogens
Signs and Symptoms of Aminopterin Exposure: Signs and symptoms of acute exposure to aminopterin may include nausea, vomiting, anorexia, stomatitis (inflammation of the oral mucosa), pharyngitis (inflammation of the pharynx), erythematous rashes (red rashes on the skin), hyperpigmentation (abnormally increased pigmentation), chills, fever, gastrointestinal hemorrhage, and renal failure (especially in high doses). May induce abortion in pregnant women.
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
For emergency situations, wear a positive pressure, pressure-demand, full facepiece self-contained breathing apparatus (SCBA) or pressure- demand supplied air respirator with escape SCBA and a fully-encapsulating, chemical resistant suit. (EPA, 1998)
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 650(SRC), determined from a structure estimation method(2), indicates that aminopterin is expected to have low mobility in soil(SRC). A measured pKa of one of the carboxylic acid moieties of aminopterin is 5.5(3), indicates that this compound will primarily exist in anion form in the environment and anions do not volatilize from moist soil surfaces. Aminopterin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.3X10-19 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2005).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 650(SRC), determined from a structure estimation method(2), indicates that aminopterin is expected to adsorb to suspended solids and sediment(SRC). A measured pKa of one of the carboxylic acid moieties of aminopterin is 5.5(3), indicate that this compound will primarily exist in anion form in the environment and anions do not volatilize from water surfaces and generally do not adsorb more strongly to suspended solids and sediment than their neutral counterparts(4). According to a classification scheme(5), an estimated BCF of 3.2(SRC), from an estimated log Kow of -1.82(6) and a regression-derived equation(7), suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), aminopterin, which has an estimated vapor pressure of 2,3X10-19 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase aminopterin may be removed from the air by wet and dry deposition(SRC). Aminopterin absorbs UV light >290 nm(3); therefore, aminopterin may be susceptible to photolysis by sunlight(SRC).
Aminopterin is an amino derivative of folic acid which binds competitively to the dihydrofolate reductase enzyme to block tetrahydrofolate synthesis. Tetrahydrofolate is essential in the production of purines and pyrimadines, thus it's deficiency results in a reduction of DNA, RNA and protein synthesis.
Using a structure estimation method based on molecular connectivity indices(1), the Koc for aminopterin can be estimated to be 650(SRC). According to a classification scheme(2), this estimated Koc value suggests that aminopterin is expected to have low mobility in soil. A pKa of one of the carboxylic acid moieties of aminopterin was reported as 5.5(3), indicating that this compound will primarily exist in the dissociated form in the environment and anions generally do not adsorb more strongly to organic carbon and clay than their neutral counterparts(4).
/SIGNS AND SYMPTOMS/ Effect of drug on fetus: ...Aminopterin syndrome: cranial dystosis, hydrocephalus, hypertelorism, anomalies of external ear, micrognathia, posterior cleft palate. /from table/
/SIGNS AND SYMPTOMS/ Overdosage with... aminopterin causes leukopenia, granulocytopenia, thrombocytopenia, hypoplasia of all elements of bone marrow, nausea and vomiting, and anorexia. ...Lymphopenia, fetal death or abnormalities, stomatitis /are also listed/.
/SIGNS AND SYMPTOMS/ Known effects of aminopterin in man that are well documented and conclusive (embryonic development in the first trimester of pregnancy): multiple anomalies, craniofacial anomalies, abortion, intrauterine growth retardation. /From table/
/SIGNS AND SYMPTOMS/ First trimester use of the folate antagonists, aminopterin and methotrexate, is known to cause spontaneous abortions and congenital abnormalities... however, normal pregnancy outcome has been reported after use in the second and third trimesters.
For more Human Toxicity Excerpts (Complete) data for AMINOPTERIN (7 total), please visit the HSDB record page.
Aminopterin's former production and use as a research drug for the treatment of leukemias(1) may have resulted in its release to the environment through various waste streams; its former(2) use as a rodenticide(3) resulted in its direct release to the environment(SRC).
An estimated BCF of 3 was calculated for aminopterin(SRC), using an estimated log Kow of -1.8(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).
A measured pKa of one of the carboxylic acid moieties of aminopterin is 5.5(1), indicates that this compound will primarily exist in anion form in the environment and anions do not volatilize from water or moist soil surfaces(SRC). Aminopterin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.3X10-19 mm Hg(SRC), determined from a fragment constant method(2).
/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ ...Rats /were administered/ 0.1 mg/kg bw /of aminopterin/ on the 6th day and... defects of the eye, face, skull, brain, extremities, abdominal wall and tail /were observed/. A complete mitotic block was noted in the ectotrophoblast but not the embryoblast.
/ALTERNATIVE IN VITRO TESTS/ /Studies were performed/... of cultures... of eight-cell-blastomeres of rat embryos in Bigger's medium with the addition of 20% rat serum from animals treated with different doses of this drug (aminopterin). Retardation of cleavage rate, abnormalities of blastocyst formation and damage of inner cell mass was observed.
/OTHER TOXICITY INFORMATION/ A quite new approach to biological control /of pests/ is by means of chemosterilants. The sustained release of large numbers of sterilized males of specific insect species has yielded remarkable control of certain insect pests of domestic animals and crop plants. ...Sterilization can be effected in two ways; physically, by means of radiation, x-rays, or gamma rays or chemically, by feeding compounds of known chemosterilant activity, such as the folic acid antagonist aminopterin...
Aminopterin is not expected to undergo hydrolysis in the environment due to the lack of hydrolyzable functional groups(1). Aminopterin absorbs UV light >290 nm(2); therefore, on soil surfaces, aminopterin may be susceptible to photolysis(SRC).
Occupational exposure to aminopterin may have occurred through inhalation and dermal contact with this compound at workplaces where aminopterin was produced or used. Exposure of the general population to this compound was limited to those receiving this drug in the treatment of certain leukemias. (SRC)
Releases of CERCLA hazardous substances are subject to the release reporting requirement of CERCLA section 103, codified at 40 CFR part 302, in addition to the requirements of 40 CFR part 355. Aminopterin is an extremely hazardous substance (EHS) subject to reporting requirements when stored in amounts in excess of its threshold planning quantity (TPQ) of 500 or 10,000 lbs. Extremely hazardous substances that are solids are subject to either of two threshold planning quantities ... The lower quantity applies only if the solid exists in powdered form and has a particle size less than 100 microns; or is handled in solution or in molten form; or meets the criteria for a National Fire Protection Association (NFPA) rating of 2, 3 or 4 for reactivity. If the solid does not meet any of these criteria, it is subject to the upper ... threshold planning quantity ... .
L-Glutamic acid, N-[4-[[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-: ACTIVE
... US Patent 2,575,368 to American Cyanamid
使用Aminopterin has been used in the production of anti- neurogranin antibodies.
一般的な説明Clusters of yellow needles. Used as a rodenticide, medicine and rodenticide. Not registered as a rodenticide in the U.S.
純化方法Purify aminopterin by recrystallisation from H2O. It has properties similar to those of methotrexate (above). It has UV at max 244, 290 and 355nm ( 18600, 21300 and 12000) in H2O at pH 1; 260, 284 and 370nm ( 28500, 26400 and 8600) in H2O at pH 13. [Seeger et al. J Am Chem Soc 71 1753 1949, Angier & Curran J Am Chem Soc 8 1 2814 1959, Blakley The Biochemistry of Folic Acid and Related Pteridines, North-Holland Publ Co., Amsterdam, NY, pp 157-163 1969.] For small quantities, chromatograph it on DEAE cellulose with a linear gradient of ammonium bicarbonate pH 8 and increase the molarity from 0.1 to 0.4. Monitoring is by following the UV absorption of the fractions. For larger quantities, a near boiling solution of aminopterin (5g) in H2O (400mL) is slowly treated with small portions of MgO powder (~0.7g, calcined magnesia) with vigorous stirring until a small amount of MgO remained undissolved and the pH rises from 3-4 to 7-8. Charcoal (1g) is added to the hot solution and filtered immediately through a large sintered glass funnel of medium porosity and lined with a hot wet pad of Celite (~2-3 mm thick). The filtrate is cooled in ice, and the crystals of the Mg salt are collected by filtration and recrystallised from boiling H2O (200mL). The crystals are washed with EtOH and dried in vacuo. The Mg salt is redissolved in boiling H2O (200mL) and carefully acidified with vigorous agitation with AcOH (2mL). Pure aminopterin (3g) separates in fine yellow needles (dihydrate) which are easily filtered. The solid is washed with cold H2O, then Me2CO and dried in vacuo. If a trace of impurity is still present as shown by DEAE cellulose chromatography or TLC, repetition of the process will remove it; see UV above. [Loo J Med Chem 8 139 1965, Beilstein 26 IV 3831.] CARCINOGENIC.
定義ChEBI: 4-aminofolic acid is a dicarboxylic acid. It has a role as a mutagen and an EC 1.5.1.3 (dihydrofolate reductase) inhibitor. It is functionally related to a folic acid.